SOTAC Stock Overview
Sotac Pharmaceuticals Limited manufactures and sells a range of pharmaceutical products in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Sotac Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹126.00 |
| 52 Week High | ₹155.00 |
| 52 Week Low | ₹97.00 |
| Beta | 0 |
| 1 Month Change | -5.97% |
| 3 Month Change | 1.61% |
| 1 Year Change | 9.57% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 4.35% |
Recent News & Updates
Shareholder Returns
| SOTAC | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.6% | 0.8% | 0.5% |
| 1Y | 9.6% | 58.6% | 44.7% |
Return vs Industry: SOTAC underperformed the Indian Pharmaceuticals industry which returned 58.6% over the past year.
Return vs Market: SOTAC underperformed the Indian Market which returned 44.7% over the past year.
Price Volatility
| SOTAC volatility | |
|---|---|
| SOTAC Average Weekly Movement | 11.9% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in IN Market | 9.9% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: SOTAC has not had significant price volatility in the past 3 months.
Volatility Over Time: SOTAC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 53 | Sharadkumar Patel | sotacpharma.com |
Sotac Pharmaceuticals Limited manufactures and sells a range of pharmaceutical products in India and internationally. The company offers non-beta-lactam tablets; beta-lactam tablets; non-beta-lactam capsules; beta-lactam capsules; oral liquids; dry syrups; and external preparations, such as nasal sprays, relief sprays, and creams. Its therapeutic portfolio includes anti-diabetic, anti-psychotic, vitamins, minerals, iron, anti-cold, antiallergic, derma products, antacid, anti-ulcerants, PPI, anti-emetics, cardiac, anti-hypertensives, analgesic, antipyretic, anti-inflammatory, anti-bacterial, anti-viral, general antibiotics IP-lactams and non-IP-lactams, anti-fungal, and cephalosporin.
Sotac Pharmaceuticals Limited Fundamentals Summary
| SOTAC fundamental statistics | |
|---|---|
| Market cap | ₹1.39b |
| Earnings (TTM) | ₹31.34m |
| Revenue (TTM) | ₹954.69m |
44.4x
P/E Ratio1.5x
P/S RatioIs SOTAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOTAC income statement (TTM) | |
|---|---|
| Revenue | ₹954.69m |
| Cost of Revenue | ₹700.33m |
| Gross Profit | ₹254.36m |
| Other Expenses | ₹223.02m |
| Earnings | ₹31.34m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.84 |
| Gross Margin | 26.64% |
| Net Profit Margin | 3.28% |
| Debt/Equity Ratio | 44.5% |
How did SOTAC perform over the long term?
See historical performance and comparison